STOCK TITAN

Fennec Pharmaceuticals (NASDAQ: FENC) director granted 20,000 stock options at $8.70

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. director Jodi A. Cook received a compensation-related grant of stock options. On June 10, 2026, Cook was granted a non-qualified stock option to purchase 20,000 common shares at an exercise price of $8.70 per share under the company’s Equity Incentive Plan. The option is 100% vested on the grant date and expires on June 10, 2036. Following this award, Cook holds stock options covering a total of 160,000 shares.

Positive

  • None.

Negative

  • None.
Insider Cook Jodi A
Role null
Type Security Shares Price Value
Grant/Award Stock Options 20,000 $8.70 $174K
Holdings After Transaction: Stock Options — 160,000 shares (Direct, null)
Footnotes (1)
  1. On June 10, 2026, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. The option is 100% vested on date of grant.
Option grant size 20,000 options Non-qualified stock options granted June 10, 2026
Exercise price $8.70 per share Strike price for 20,000 options
Expiration date June 10, 2036 Option term end for this grant
Underlying shares 20,000 common shares Shares subject to this option grant
Total options after grant 160,000 options Total stock options held following transaction
non-qualified stock option financial
"Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Equity Incentive Plan financial
"pursuant to the issuer's Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
exercise price financial
"conversion_or_exercise_price": "8.7000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested financial
"The option is 100% vested on date of grant."
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cook Jodi A

(Last)(First)(Middle)
C/O FENNEC PHARMACEUTICALS, INC.
PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options(1)$8.706/10/2026A20,00006/10/2026(2)06/10/2036Common Shares20,000$8.7160,000D
Explanation of Responses:
1. On June 10, 2026, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.
2. The option is 100% vested on date of grant.
/s/ Jodi Cook06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did FENNEC PHARMACEUTICALS (FENC) director Jodi Cook report in this Form 4?

Director Jodi A. Cook reported receiving a grant of non-qualified stock options for 20,000 FENNEC PHARMACEUTICALS common shares. The award is a compensation-related acquisition under the company’s Equity Incentive Plan, not an open-market stock purchase or sale.

How large is Jodi Cook’s new stock option grant at FENNEC PHARMACEUTICALS (FENC)?

The grant covers options to purchase 20,000 FENNEC PHARMACEUTICALS common shares. Each option has an exercise price of $8.70 per share, as disclosed in the Form 4, and represents an additional equity incentive for the director.

What is the exercise price and expiration date of Jodi Cook’s FENC stock options?

The stock options have an exercise price of $8.70 per FENNEC PHARMACEUTICALS common share and expire on June 10, 2036. These terms define the cost to acquire shares and the timeframe during which the options can be exercised.

When do Jodi Cook’s FENNEC PHARMACEUTICALS (FENC) options vest?

The options are 100% vested on the grant date of June 10, 2026. Immediate vesting means Cook has the right to exercise all 20,000 options, subject to the exercise price and expiration date set in the award.

How many FENC stock options does Jodi Cook hold after this transaction?

After this grant, Jodi A. Cook holds stock options covering a total of 160,000 FENNEC PHARMACEUTICALS common shares. This total includes the newly granted 20,000 options reported in the Form 4 filing.

Is Jodi Cook’s Form 4 transaction a market buy or sell of FENC shares?

The Form 4 reports a grant of non-qualified stock options, not a market buy or sell of FENC shares. The transaction is coded as a grant or award acquisition and reflects equity-based compensation rather than open-market trading.